Plain-English translation of NCT06571396 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research is tracking patients with hepatocellular carcinoma (liver cancer) who received immune checkpoint inhibitor therapy before surgery. The study wants to understand what surgical complications and risks occur when immune therapy is given before an operation, and to identify which patients are at higher risk. By studying these patterns, researchers hope to predict and prevent problems in future patients.
Immune-based treatments have shown promise in shrinking liver tumors before surgery, but doctors don't yet know what surgical complications these treatments might cause—such as excessive bleeding, tissue swelling, or adhesions during the operation. This study will collect detailed information to help doctors better prepare patients and reduce risks.
You likely qualify if…
You likely don't qualify if…
As a participant, you will be part of a research cohort—meaning researchers will collect and analyze information about your surgical recovery and any complications after your immune therapy and cancer operation. The study does not involve giving you new medication; instead, it gathers data from your medical records, your health status after surgery, and your outcomes over time to help understand perioperative risks.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China
Sponsor
Qilu Hospital of Shandong University
Enrollment target
~200 participants
Started
April 2014
Primary completion
August 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Tao Li
Shandong University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.